Germany's Merck KGaA has agreed to acquire Bio-Techne for $11.3 billion, causing Bio-Techne shares to surge before the market opened. This acquisition highlights Merck's strategic expansion in the biotech sector. The deal is significant for investors as it may reshape competitive dynamics in the industry and potentially drive growth for Merck. Further details on the transaction's completion and integration plans are awaited.

More News (TECH)

Bio-Techne deal with Merck faces legal probe over board duties and deal terms

Ademi LLP is investigating Bio-Techne's $11.3 billion sale to Merck for possible breaches of fiduciary duty by the board and unfair deal terms. Shareholders will get $73 per share, but insiders may gain extra benefits. The deal restricts competing bi...

Market News

Bearish

20 hours ago